Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.59 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6244793 | 0.81 | ALDH1A1 (0.61) | CES2CES1LMNAMAPTKDM4E | |
| SCHEMBL13893380 | 0.81 | CES2 (0.59) | CES2CES1LMNAMAPTKDM4E | |
| SCHEMBL585346 | 0.81 | CES2 (0.59) | CES2CES1LMNAMAPTKDM4E | |
| SCHEMBL22462223 | 0.79 | MAPT (0.66) | CES2CES1LMNAMAPTKDM4E | |
| SCHEMBL30668590 | 0.79 | MAPT (0.66) | CES2CES1LMNAMAPTKDM4E | |
| SCHEMBL27621482 | 0.79 | CES2 (0.69) | CES2CES1LMNAMAPTKDM4E | |
| SCHEMBL14305290 | 0.79 | MAPT (0.61) | CES2CES1LMNAMAPTKDM4E | |
| SCHEMBL22478745 | 0.79 | MAPT (0.61) | CES2CES1LMNAMAPTKDM4E | |
| SCHEMBL19787945 | 0.78 | MAPT (0.64) | CES2CES1LMNAMAPTKDM4E | |
| SCHEMBL11334868 | 0.78 | MAPT (0.69) | CES2CES1LMNAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108245518-A | Utilize the method for two one for treating cancers of 3- (4- ((4- (morpholinomethyl) benzyl) oxygroup) -1- oxoisoindoline diindyl -2- bases) piperidines -2,6- | 细胞基因公司 | 2018-07-06 | — | — | CN | claimed |
| CN-107935994-A | The synthesis of 3 (5 amino, 2 methyl 4 oxoquinazolin 3 (4H) base) piperidines, 2,6 diketone | 细胞基因公司 | 2018-04-20 | — | — | CN | claimed |
| CN-105377831-B | Synthesis of 3- (5-amino-2-methyl-4-oxoquinazolin-3 (4H) -yl) piperidine-2, 6-dione | 细胞基因公司 | 2018-02-02 | — | — | CN | claimed |
| CN-105209462-A | Novel inhibitor compounds of phosphodiesterase type 10A | ABBVIE DEUTSCHLAND | 2015-12-30 | — | — | CN | claimed |
| WO-2003082824-A1 | SYNTHESIS OF 2,6-DICARBONYLPYRIDINES | BOULDER SCIENTIFIC COMPANY (US) | 2003-10-09 | — | — | WO | claimed |
| WO-2026101698-A1 | HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12522618-B2 | Copper complexes for treatment of neurodegenerative disorders | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2026-01-13 | — | — | US | disclosed |
| CN-120005601-A | Acidizing corrosion inhibitor for oil field and preparation method thereof | 黑龙江克瑞休斯石油科技有限公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20240368195-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INST (US) | 2024-11-07 | — | — | US | disclosed |
| US-12054472-B2 | 1,2,4-triazine-4-amine derivatives | NXERA PHARMA UK LIMITED (GB) | 2024-08-06 | — | — | US | disclosed |
| US-12012422-B2 | Copper complexes for treatment of neurodegenerative disorders | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2024-06-18 | — | — | US | disclosed |
| EP-4204399-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS Therapy Development Institute (US) | 2023-07-05 | — | — | EP | disclosed |
| US-5696240-A | Macrocyclic complexes of yttrium, the lanthanides and the actinides having peripheral coupling functionalities | VALLARINO LIDIA M (US) | 1997-12-09 | — | — | US | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| CN-1101038-A | 4-substituted 6,9-bis(substituted-amino) benzo(g) isoquinoline-5, 10-Di-ones | UNIV VERMONT (US) | 1995-04-05 | — | — | CN | disclosed |
| US-5373093-A | Macrocyclic complexes of yttrium, the lanthanides and the actinides having peripheral coupling functionalities | NEWPORT INSTRUMENTS | 1994-12-13 | — | — | US | disclosed |
| EP-0369000-A4 | MACROCYCLIC COMPLEXES OF YTTRIUM, THE LANTHANIDES AND THE ACTINIDES HAVING PERIPHERAL COUPLING FUNCTIONALITIES | — | 1993-06-02 | — | — | EP | disclosed |
| EP-0369000-A1 | MACROCYCLIC COMPLEXES OF YTTRIUM, THE LANTHANIDES AND THE ACTINIDES HAVING PERIPHERAL COUPLING FUNCTIONALITIES | Vallarino, Lidia M. (US) | 1990-05-23 | — | — | EP | disclosed |
| WO-1989011868-A1 | MACROCYCLIC COMPLEXES OF YTTRIUM, THE LANTHANIDES AND THE ACTINIDES HAVING PERIPHERAL COUPLING FUNCTIONALITIES | COULTER ELECTRONICS, INC. (US) | 1989-12-14 | — | — | WO | disclosed |
| EP-0225673-B1 | PROCESS FOR THE PREPARATION OF ACYL UREAS | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1989-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012422-B2 | Copper complexes for treatment of neurodegenerative disorders | SOD1, SMN1; SMN2, CLN6 | CES2 1672/4885CES1 4059/4885LMNA 1550/4885 |
| US-12054472-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2A, ADORA2B, ADORA1 | CES2 1506/4885CES1 1376/4885LMNA 1724/4885 |
| US-20240368195-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SOD1, SMN1; SMN2, CLN6 | CES2 1672/4885CES1 4059/4885LMNA 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.